Journal of Antimicrobial Chemotherapy (1985) 16, 463-468
© 1985 The British Society for Antimicrobial Chemotherapy
research-article |
In-vitro activity of BMY 28142, a new aminothiazolyl cephalosporin

*Clinical Microbiology Laboratory, Department of Pathology, Medical College of Georgia Augusta, Georgia 30912
Department of Medicine, Veterans Administration Medical Center and Medical College of Georgia Augusta, Georgia 30910, U.S.A.
accepted 17 April 1985
The in-vitro activity of BMY 28142, a new
-methoxyimino aminothiazolyl cephalosporin, was determined by microdilution broth techniques. The agent demonstrated excellent activity against recent clinical Enterobacteriaceae isolates with a 90% minimum inhibitory concentration (MIC90) of 0·25 mg/l or less for all but one species tested. BMY 28142 inhibited all Pseudomonas aeruginosa strains tested (MIC90=8·0 mg/l) as well as most other non-fermentative bacteria studied. Methicillin-susceptible Staphylococcus aureus were susceptible to BMY 28142 with MIC90=4·0 mg/l, while methicillin-resistant strains were generally resistant (MIC range 8>32 mg/l).